Price
$77.20
Decreased by -6.90%
Dollar volume (20D)
221.02 M
ADR%
6.28
Earnings report date
Feb 24, 2025
Shares float
32.55 M
Shares short
8.43 M [25.89%]
Shares outstanding
33.56 M
Market cap
2.78 B
Beta
2.07
Price/earnings
87.28
20D range
75.61 134.21
50D range
75.61 169.29
200D range
69.43 177.37

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally.

The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.

Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers.

The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity.

The company was founded in 1998 and is headquartered in Andover, Massachusetts.

  • Quarterly earnings
  • Annual earnings
Reported date EPSChange YoY EstimateSurprise
Jul 31, 24 0.35
Increased by +1.27 K%
0.21
Increased by +66.67%
Apr 30, 24 0.35
Increased by +537.50%
-0.04
Increased by +975.00%
Feb 26, 24 0.12
Increased by +157.14%
-0.03
Increased by +500.00%
Nov 6, 23 -0.78
Decreased by -212.00%
-0.16
Decreased by -387.50%
Aug 3, 23 -0.03
Increased by +92.68%
-0.13
Increased by +76.92%
May 1, 23 -0.08
Increased by +78.95%
-0.25
Increased by +68.00%
Feb 22, 23 -0.21
Increased by +54.35%
-0.30
Increased by +30.00%
Nov 3, 22 -0.25
Increased by +46.81%
-0.41
Increased by +39.02%
  • Quarterly financials
  • Annual financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 24 108.76 M
Increased by +63.72%
4.22 M
Increased by +116.58%
Increased by +3.88%
Increased by +110.13%
Jun 30, 24 114.31 M
Increased by +117.87%
12.19 M
Increased by +1.32 K%
Increased by +10.67%
Increased by +659.13%
Mar 31, 24 96.85 M
Increased by +133.07%
12.20 M
Increased by +562.71%
Increased by +12.59%
Increased by +298.53%
Dec 31, 23 81.17 M
Increased by +158.72%
4.03 M
Increased by +159.99%
Increased by +4.97%
Increased by +123.19%
Sep 30, 23 66.43 M
Increased by +158.65%
-25.42 M
Decreased by -242.34%
Decreased by -38.27%
Decreased by -32.35%
Jun 30, 23 52.47 M
Increased by +155.66%
-1.00 M
Increased by +91.31%
Decreased by -1.91%
Increased by +96.60%
Mar 31, 23 41.55 M
Increased by +161.68%
-2.64 M
Increased by +75.04%
Decreased by -6.34%
Increased by +90.46%
Dec 31, 22 31.38 M
Increased by +224.52%
-6.72 M
Increased by +46.95%
Decreased by -21.42%
Increased by +83.65%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY